



Evolus Appoints Dan Stewart as Vice President and General Manager, International

May 19, 2021

NEWPORT BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the company's International business.

"Dan has an extensive track record of success and a global reputation built from 20 years of experience in aesthetics," said Crystal Muilenburg, Chief Marketing Officer. "We look forward to Dan leading the expansion of Evolus' global footprint starting with the launch of Nuceiva™ in Europe in early 2022."

Dan is a seasoned operational leader with more than 20 years of experience in medical aesthetics including dermal fillers, botulinum toxin, breast implants and energy-based devices. Dan started his career with Ipsen where he supported the international assessment of Dysport® for medical aesthetics. Dan held various sales leadership roles for Allergan's aesthetics division (previously Inamed) and ascended to the role of UK Business Unit Director. While at Allergan, Dan launched Natrelle® silicone breast implants, Vistabel®, Juvederm® Ultra and Vycross® across Europe. Dan served on Allergan's International Strategic Marketing Board where he consulted on International commercial strategies and new product launches. Dan was also Chief Marketing Officer at Teoxane before starting his own consultancy firm focused within the European aesthetic market.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words "plans," "expects," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed," or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company's forward-looking statements include, but are not limited to, statements made by Mrs. Muilenburg regarding the expansion of the Company's footprint into Europe in early 2022. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, including the effect on our pricing, discounts we may offer to our customers and the volume of purchases by our customers, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Jeuveau®, the efficiency and operability of our digital platform, competition and market dynamics, and our ability to maintain regulatory approval of Jeuveau® and other risks described in the section entitled "Risk Factors" in our Annual Report on Form 10-Q for the Quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on May 12, 2021, which is available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If the company does update or revise one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

Jeuveau® is a registered trademark and Nuceiva™ is a trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd

Dysport®, Natrelle®, Vistabel®, Juvederm® and Vycross® are registered trademarks of their respective owners.

Evolus, Inc. Contacts:

Investor Contact:

Lauren Silvermail, Evolus, Inc.

Chief Financial Officer and EVP Corporate Development

Tel: +1-949-284-4726

Email: IR@Evolus.com

Media Contact:

Crystal Muilenburg, Evolus, Inc.

Chief Marketing Officer

Tel: +1-949-284-4506

Email: media@evolus.com



Source: Evolus